Advancing genetic medicines for rare diseases
Solid Biosciences (solidbio.com) scores 77 out of 100 on Brand Analyzer, placing it in the Brand-Ready tier among Healthcare brands, in the 53rd percentile of 9029 Healthcare brands.
Solid Biosciences is a precision genetic medicine company focused on developing gene therapy candidates for rare neuromuscular and cardiac diseases. Its lead program, SGT-003, targets Duchenne muscular dystrophy. The company aims to translate gene therapy science into treatments for patients with high unmet medical needs, engaging with patients, families, healthcare providers, researchers, and biopharmaceutical partners in this effort.
| Brand Name | Solid Biosciences |
|---|---|
| Domain | solidbio.com |
| Industry | Healthcare |
| Main Competitors | Sarepta Therapeutics (83/100), Pfizer (89/100), REGENXBIO, Taysha Gene Therapies, Rocket Pharmaceuticals, Avidity Biosciences |
Moz Domain Authority 43/100 vs category average 40 / leader 95 - a strong backlink profile, so AI systems frequently encounter mentions of the brand.
Ranked #1,282,956 on the Tranco list of most-visited sites - modest traffic makes the brand easy for AI models to overlook.
No Wikipedia presence was found - a major gap, since Wikipedia is among the most heavily weighted sources in AI training data.
The homepage meta description reads "Focused on advancing genetic medicines for neuromuscular and cardiac diseases Focused on advancing genetic medicines for neuromuscular and cardiac diseases [jsoncontentimporterpro …" (No meta description. OG description present and descriptive) - this is the summary AI engines are most likely to quote.
Structured data on the homepage: 1 JSON-LD block(s), Organization schema, Breadcrumb/Website schema, + Microdata, og:title, og:description, og:image, og:type, Twitter cards, canonical. Adding FAQ schema would further help AI crawlers parse the brand's identity.
AI-crawler access: robots.txt present, no AI bot restrictions - robots.txt controls whether engines like GPTBot and ClaudeBot can read the site at all.
Detected tech stack: Cloudflare, WordPress, Ghost.
Social footprint: verified profiles on LinkedIn, X (Twitter), Facebook, Instagram, YouTube; no detected presence on GitHub - consistent profiles reinforce the brand's identity across the web.
0 Reddit mentions - community discussion signals real-world reputation to AI models.
Live results from asking a general-purpose AI assistant about the brand, checked September 2026.
When asked "What is Solid Biosciences?", Claude could identify the brand as of September 2026. Solid Biosciences is a biotechnology company focused on developing gene therapies for Duchenne muscular dystrophy, with its lead candidate being SGT-003, an AAV-based gene therapy targeting microdystrophin delivery. Best known for Developing gene therapy treatments for Duchenne muscular dystrophy, including its microdystrophin gene therapy programs.
When asked "Best brands similar to Solid Biosciences?", Claude would recommend Solid Biosciences as of September 2026. It's a notable name in the Duchenne muscular dystrophy gene therapy space, so it would come up alongside companies like Sarepta Therapeutics and Pfizer when discussing that treatment area.
Common questions people ask in Google, ChatGPT, Claude, Gemini, Perplexity, and other AI search engines.
Solid Biosciences's main competitors in Healthcare: Sarepta Therapeutics (83/100), Pfizer (89/100).
Sources: Brand Analyzer scan
Solid Biosciences is a precision genetic medicine company that develops gene therapy candidates for rare neuromuscular and cardiac diseases.
Sources: Solid Biosciences official site
Solid Biosciences has limited AI-search visibility, scoring 29/100 on Brand Analyzer's AI visibility composite (visibility 0, trust 54, recommendation 50). This estimates how likely AI engines like ChatGPT, Claude, Gemini and Perplexity are to know, trust, and recommend the brand.
Sources: Solid Biosciences official site
Solid Biosciences offers a pipeline of gene therapy candidates for rare neuromuscular and cardiac diseases, with SGT-003 as its lead product candidate.
Sources: Solid Biosciences official site
Solid Biosciences advances a portfolio of gene therapy candidates, including its lead program SGT-003, aimed at treating rare neuromuscular and cardiac diseases with limited existing treatment options.
Sources: Solid Biosciences official site
Solid Biosciences scores 50/100 on Brand Analyzer's AI recommendation signal, indicating it is reasonably likely to be surfaced when AI assistants like ChatGPT suggest Healthcare options. Recommendation depends on crawlability, structured data, and category authority.
Sources: Solid Biosciences official site
Solid Biosciences can improve AI discoverability by strengthening structured data (Organization and FAQ schema), maintaining an accurate Wikipedia/Wikidata entity, earning authoritative citations, and keeping content crawlable for AI bots. Brand Analyzer measures these as visibility, trust, and recommendation signals.
Sources: Solid Biosciences official site
Solid Biosciences is known for its focus on gene therapy for rare neuromuscular and cardiac diseases, particularly its lead candidate SGT-003.
Sources: Solid Biosciences official site
Solid Biosciences' work is intended for patients and families affected by rare neuromuscular and cardiac diseases, as well as healthcare providers, researchers, and biopharmaceutical partners who engage with its gene therapy programs.
Sources: Solid Biosciences official site
Solid Biosciences scores 29/100 for AI visibility - how well ChatGPT, Claude, Perplexity and Google AI Overviews can discover, identify and cite the brand.
Solid Biosciences has a weak AI-visibility profile at 29/100 - a proxy for how readily ChatGPT, Perplexity and Google's AI Overviews can recognise and cite it. Its strongest area is trust (54/100) and its weakest is visibility (0/100). It benefits from a global traffic rank of #1,282,956 (Tranco), a Moz Domain Authority of 43/100 and open access for AI crawlers (GPTBot, ClaudeBot, etc.). The main gaps holding it back: no clear Wikipedia entity to anchor it in LLM training data, no strong Wikidata entry and no llms.txt to steer AI to its best pages. In a live check, Claude could already identify Solid Biosciences from memory (September 2026) - a sign these signals are paying off.
The score combines seven dimensions - name quality, digital presence, visual identity, messaging clarity, trust foundation, AI discoverability, and brand authority - into a single objective benchmark.
Ranked closest to Solid Biosciences: SCC Soft Computer (77/100), Smiling Mind (77/100), Straight Teeth Direct (77/100), Strand Life Sciences (77/100).
A step up - brands to learn from: Zymo Research (81/100), Zurich Insurance Group (81/100).
Category leader: Booksy (96/100).
Brand Analyzer is built by DataEase AI. Track your brand in ChatGPT, Gemini and Perplexity.